Citations

Showing 10 of 108094 citations.

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Chen, Denise, Corona, Rosario I. , Fu, Zhuxuan , Murali, Rajmohan , Köbel, Martin , Tazi, Yanis , Cunningham, Julie M. , Wiley, Brian , Armasu, Sebastian M. , Lester, Jenny , Laslavic, Angela , Kennedy, Catherine J. , Piskorz, Anna , Sekowska, Magdalena , Brand, Alison H. , Chiew, Yoke-Eng , Drapkin, Ronny , Gourley, Charlie , Brenton, James D. , Weigelt, Britta , Anglesio, Michael S. , Huntsman, David G. , Gayther, Simon A. , Lawrenson, Kate , Goode, Ellen L. , Papaemmanuil, Elli , Bolton, Kelly L , Corona de la Fuente, Rosario , Fu, Zhuxuan , Murali, Rajmohan , Köbel, Martin , Tazi, Yanis , Cunningham, Julie M , Moukarzel, Lea A , Winham, Stacey J , Elishaev, Esther , Kennedy, Catherine J , Sekowska, Magdalena , Brand, Alison H , Chiew, Yoke-Eng , Pharoah, Paul D P , Elias, Kevin M , Drapkin, Ronny , Churchman, Michael , Gourley, Charlie , Fazio, Anna de , Karlan, Beth Y , Brenton, James D , Weigelt, Britta , Anglesio, Michael S , Modugno, Francesmary , Lawrenson, Kate , Goode, Ellen L , Bolton, Kelly L. , Chan, Irenaeus C.C. , Moukarzel, Lea A. , Winham, Stacey J. , Elishaev, Esther , Pharoah, Paul D.P. , Elias, Kevin M. , DeFazio, Anna , Karlan, Beth Y. , Konner, Jason A , Modugno, Francesmary

Mayo Clinic

Clinical Cancer Research | July 11, 2022 | Volume: 28 | Issue: 22 | Pages: 4947-4956

10.1158/1078-0432.ccr-21-3817 | PMID 35816189 Get It

Abstract Purpose: To identify molecular subclasses of clear cell ovarian carcinoma (CCOC) and assess their impact on clinical presentation and outcomes. Experimental Design: We profiled 421 primary CCOCs that passed quality control using a targeted deep sequencing panel of 163 putative CCOC driver genes and whole transcriptome sequencing of 211 of these tumors. Molecularly defined subgroups were identified and tested for association with clinical characteristics and overall survival. Results: We detected a putative somatic driver mutation in at least one candidate gene in 95% (401/421) of CCOC tumors including ARID1A (in 49% of tumors), PIK3CA (49%), TERT (20%), and TP53 (16%). Clustering of cancer driver mutations and RNA expression converged upon two distinct subclasses of CCOC. The first was dominated by ARID1A-mutated tumors with enriched expression of canonical CCOC genes and markers of platinum resistance; the second was largely comprised of tumors with TP53 mutations and enriched for the expression of genes involved in extracellular matrix organization and mesenchymal differentiation. Compared with the ARID1A-mutated group, women with TP53-mutated tumors were more likely to have advanced-stage disease, no antecedent history of endometriosis, and poorer survival, driven by their advanced stage at presentation. In women with ARID1A-mutated tumors, there was a trend toward a lower rate of response to first-line platinum-based therapy. Conclusions: Our study suggests that CCOC consists of two distinct molecular subclasses with distinct clinical presentation and outcomes, with potential relevance to both traditional and experimental therapy responsiveness. See related commentary by Lheureux, p. 4838
Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection
Karp, Emily E. , Gompel, Jamie J. Van , Van Gompel, Jamie J , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Reports | July 11, 2022 | Volume: 83 | Issue: 03 | Pages: e80-e82

10.1055/s-0042-1753519 | PMID 35832684 Get It

AbstractEsthesioneuroblastoma is a rare malignancy originating from the olfactory epithelium. Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.
From theory to practical fundamentals of electroencephalographic source imaging in localizing the epileptogenic zone
Singh, Jaysingh , Ebersole, John S. , Brinkmann, Benjamin H. , Brinkmann, Benjamin H

Mayo Clinic

Epilepsia | July 11, 2022 | Volume: 63 | Issue: 10 | Pages: 2476-2490

10.1111/epi.17361 | PMID 35811476 Get It

AbstractWith continued advancement in computational technologies, the analysis of electroencephalography (EEG) has shifted from pure visual analysis to a noninvasive computational technique called EEG source imaging (ESI), which involves mathematical modeling of dipolar and distributed sources of a given scalp EEG pattern. ESI is a noninvasive phase I test for presurgical localization of the seizure onset zone in focal epilepsy. It is a relatively inexpensive modality, as it leverages scalp EEG and magnetic resonance imaging (MRI) data already collected typically during presurgical evaluation. With an adequate number of electrodes and combined with patient‐specific MRI‐based head models, ESI has proven to be a valuable and accurate clinical diagnostic tool for localizing the epileptogenic zone. Despite its advantages, however, ESI is routinely used at only a minority of epilepsy centers. This paper reviews the current evidence and practical fundamentals for using ESI of interictal and ictal epileptic activity during the presurgical evaluation of drug‐resistant patients. We identify common errors in processing and interpreting ESI studies, describe the differences in approach needed for localizing interictal and ictal EEG discharges through practical examples, and describe best practices for optimizing the diagnostic information available from these studies.
Molecular characterization and reclassification of a 1.18 Mbp DMD duplication following positive carrier screening for Duchenne/Becker muscular dystrophy
Zepeda‐Mendoza, Cinthya , Bontrager, Jordan E., Fisher, Camille F., McDonald, Amber , George‐Abraham, Jaya K. , Hasadsri, Linda , Zepeda-Mendoza, Cinthya J , Fisher, Camille

Mayo Clinic

Clinical Case Reports | July 11, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/ccr3.6008 | PMID 35846917 Get It

Abstract A 2‐month‐old male patient harboring a duplication of DMD exons 1–7 classified as pathogenic by an outside institution presented with mildly elevated creatine phosphokinase (CK); molecular breakpoint analysis by our laboratory reclassified the duplication as likely benign. To date, proband continues to develop normally with decreased CK, further supporting our reclassification.
GRN Mutations Are Associated with Lewy Body Dementia
Reho, Paolo, Koga, Shunsuke , Shah, Zalak , Rademakers, Rosa , Beach, Thomas G., Ross, Owen A. , Scholz, Sonja W. , May, Patrick , Ross, Owen A , Scholz, Sonja W , Koga, Shunsuke , May, Patrick , Chia, Ruth , Dalgard, Clifton L. , Boeve, Bradley F. , Beach, Thomas G. , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | July 10, 2022 | Volume: 37 | Issue: 9 | Pages: 1943-1948

10.1002/mds.29144 | PMID 35810449 Get It

ABSTRACTBackgroundLoss‐of‐function mutations in GRN are a cause of familial frontotemporal dementia, and common variants within the gene have been associated with an increased risk of developing Alzheimer's disease and Parkinson's disease. Although TDP‐43‐positive inclusions are characteristic of GRN‐related neurodegeneration, Lewy body copathology has also been observed in many GRN mutation carriers.ObjectiveThe objective of this study was to assess a Lewy body dementia (LBD) case–control cohort for pathogenic variants in GRN and to test whether there is an enrichment of damaging mutations among patients with LBD.MethodsWe analyzed whole‐genome sequencing data generated for 2591 European‐ancestry LBD cases and 4032 neurologically healthy control subjects to identify disease‐causing mutations in GRN.ResultsWe identified six heterozygous exonic GRN mutations in seven study participants (cases: n = 6; control subjects: n = 1). Each variant was predicted to be pathogenic or likely pathogenic. We found significant enrichment of GRN loss‐of‐function mutations in patients with LBD compared with control subjects (Optimized Sequence Kernel Association Test P = 0.0162). Immunohistochemistry in three definite LBD cases demonstrated Lewy body pathology and TDP‐43‐positive neuronal inclusions.ConclusionsOur findings suggest that deleterious GRN mutations are a rare cause of familial LBD. © 2022 International Parkinson Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited
Domenighetti, Cloé , Douillard, Venceslas , Sreelatha, Ashwin Ashok Kumar , Schulte, Claudia , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Gagliardi, Monica , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Guedes, Leonor Correia , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri, Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Vince, Nicolas , Elbaz, Alexis , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel , Bobbili, Dheeraj Reddy , Singleton, Andrew , Gourraud, Pierre‐Antoine , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Krainc, Dimitri , Farrer, Matthew J.

Mayo Clinic

Movement Disorders | July 10, 2022 | Volume: 37 | Issue: 9 | Pages: 1929-1937

10.1002/mds.29133 | PMID 35810454 Get It

AbstractBackgroundTwo studies that examined the interaction between HLA‐DRB1 and smoking in Parkinson's disease (PD) yielded findings in opposite directions.ObjectiveTo perform a large‐scale independent replication of the HLA‐DRB1 × smoking interaction.MethodsWe genotyped 182 single nucleotide polymorphism (SNPs) associated with smoking initiation in 12 424 cases and 9480 controls to perform a Mendelian randomization (MR) analysis in strata defined by HLA‐DRB1.ResultsAt the amino acid level, a valine at position 11 (V11) in HLA‐DRB1 displayed the strongest association with PD. MR showed an inverse association between genetically predicted smoking initiation and PD only in absence of V11 (odds ratio, 0.74, 95% confidence interval, 0.59–0.93, PInteraction = 0.028). In silico predictions of the influence of V11 and smoking‐induced modifications of α‐synuclein on binding affinity showed findings consistent with this interaction pattern.ConclusionsDespite being one of the most robust findings in PD research, the mechanisms underlying the inverse association between smoking and PD remain unknown. Our findings may help better understand this association. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Merkel cell carcinoma of unknown primary: Clinical presentation and outcomes
Chen, Xiao T. , Baum, Christian L. , Brewer, Jerry D., Block, Matthew S. , Jakub, James W. , Pockaj, Barbara A. , Foote, Robert L. , Hieken, Tina J. , Jakub, James W , Hieken, Tina J , Houdek, Matthew T , Broida, Samuel E. , Markovic, Svetomir N. , Houdek, Matthew T.

Mayo Clinic

Journal of Surgical Oncology | July 9, 2022 | Volume: 126 | Issue: 6 | Pages: 1080-1086

10.1002/jso.27010 | PMID 35809230 Get It

AbstractBackgroundMerkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy that usually occurs in the head/neck or extremities. However, there are reports of MCC developing in the lymph nodes or parotid gland without evidence of a primary cutaneous lesion.MethodsWe reviewed 415 patients with biopsy‐proven MCC. Patients with MCC of unknown primary (n = 37, 9%, MCCUP) made up the study cohort. The primary endpoints of the study were rate of recurrence, disease‐free survival, and overall survival.ResultsPatients with MCCUP presented with tumors in lymph nodes (n = 34) or parotid gland (n = 3). Nodal disease was most commonly detected in the inguinal/external iliac (n = 15) or axillary (n = 14) regions. The mean age at diagnosis was 70 years and 24% were female. Patients presented with distant metastases in 24.3% of cases. Patients with stage IIIA disease treated with regional lymph node dissection (RLND) had a lower risk of disease recurrence (hazard ratio 0.26, p = 0.046). Recurrence‐free survival was 59.3% at 5 years. Disease‐specific survival was 63.3% at 5 years.ConclusionPatients with MCCUP have a high risk of recurrence and mortality. The optimal treatment for MCCUP has yet to be elucidated, although therapeutic RLND appears beneficial for these patients.
A Case of Adult Multisystem Inflammatory Syndrome Following COVID-19 Vaccine
Brown, Meghan, Garbajs, Nika Zorko , Mushtaq, Hisham, Jama, Abbas B, Rauf, Ibtisam , Mir, Mikael, Korsapati, Aishwarya Reddy, Jain, Shikha , Adhikari, Ramesh , Lal, Amos , Domecq, Juan Pablo , Goksoy, Sarah, Bartlett, Brian, Jain, Nitesh , Khan, Syed Anjum , Garbajs, Nika Z, Zec, Simon , Khedr, Anwar , Koritala, Thoyaja , Jain, Nitesh Kumar, Lal, Amos , Domecq Graces, Juan Pablo , Mir, Mikael, Gajic, Ognjen , Sharma, Amit

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | July 9, 2022 | Volume: 12 | Issue: 4 | Pages: 7-13

10.55729/2000-9666.1087 | PMID 36262897 Get It

Multisystem inflammatory syndrome is a life-threatening condition associated with elevated inflammatory markers and multiple organ injury. A diagnosis of exclusion, it has been reported after severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) in children and adults; recently it has been described in some post-COVID-19 vaccinated individuals. The prognosis with supportive care and immunomodulatory therapy is good, although some individuals may require treatment in the intensive care unit (ICU). Here we report a case of a 58-year-old man who developed multi-organ failure after receiving the second dose of the Moderna mRNA-1273 COVID-19 vaccine. He required critical organ support in the ICU. An extensive workup was done to rule out alternative infectious and inflammatory processes. Following a period of gradual in-hospital convalescence, our patient made a full recovery. To our knowledge, this is the first comprehensively described case of multisystem inflammatory syndrome associated with Moderna mRNA-1273 COVID-19 vaccine in an adult over 50 years of age.